We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Par Pharma Revives Noerr Defense Against FTC Pay-for-Delay Charges
Par Pharma Revives Noerr Defense Against FTC Pay-for-Delay Charges
In the latest action stemming from the high-profile pay-for-delay case FTC v. Actavis, Par Pharmaceuticals is looking to dismiss the commission’s case by arguing a federal court sanctioned the deal the FTC is now challenging, giving it immunity.